pela’s potential buoys speculative stock By Investing.com
Oncolytics Biotech Inc. (NASDAQ:), a clinical-stage biopharmaceutical company with a market capitalization of $68 million, is navigating the complex landscape of cancer therapeutics with its lead candidate, pela. The company’s stock shows higher volatility than the broader market with a beta of 1.58, reflecting the inherent risks in early-stage biotech investments.
Want deeper insights? InvestingPro subscribers get access to over 10 exclusive tips and comprehensive financial metrics for ONCY. The company’s focus on developing innovative treatments for metastatic breast cancer (mBC) and other indications has garnered attention from investors and analysts alike. As Oncolytics Biotech approaches critical milestones in its clinical…
